*Experimental Model of Cardiotoxicity DOI: http://dx.doi.org/10.5772/intechopen.101401*

[169] Mizusawa Y, Horie M, Wilde AA. Genetic and clinical advances in congenital long QT syndrome. Circulation Journal. 2014;**78**(12): 2827-2833. DOI: 10.1253/circj.cj-14- 0905. Epub 2014 Oct 1

[170] Lu X, Yang X, Huang X, Huang C, Sun HH, Jin L, et al. RNA interference targeting E637K mutation rescues hERG channel currents and restores its kinetic properties. Heart Rhythm. 2013;**10**(1):128-136. DOI: 10.1016/j. hrthm.2012.09.124. Epub 2012 Sep 26

[171] Denegri M, Avelino-Cruz JE, Boncompagni S, De Simone SA, Auricchio A, Villani L, et al. Viral gene transfer rescues arrhythmogenic phenotype and ultrastructural abnormalities in adult calsequestrin-null mice with inherited arrhythmias. Circulation Research. 2012;**110**(5):663- 668. DOI: 10.1161/CIRCRESAHA. 111.263939. Epub 2012 Jan 31

[172] del MonteF HSE, Schmidt U, Matsui T, Kang ZB, Dec GW, Gwathmey JK, et al. Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a. Circulation. 1999;**100**(23):2308-2311. DOI: 10.1161/01.cir.100.23.2308

[173] Chapdelaine P, Pichavant C, Rousseau J, Pâques F, Tremblay JP. Meganucleases can restore the reading frame of a mutated dystrophin. Gene Therapy. 2010;**17**(7):846-858. DOI: 10.1038/gt.2010.26. Epub 2010 Apr 15

[174] Ousterout DG, Perez-Pinera P, Thakore PI, Kabadi AM, Brown MT, Qin X, et al. Reading frame correction by targeted genome editing restores dystrophin expression in cells from Duchenne muscular dystrophy patients. Molecular Therapy. 2013;**21**(9):1718- 1726. DOI: 10.1038/mt.2013.111, . Epub 2013 Jun 4. Erratum in: Mol Ther. 2013 Nov;21(11):2130

[175] Ousterout DG, Kabadi AM, Thakore PI, Perez-Pinera P, Brown MT, Majoros WH, et al. Correction of dystrophin expression in cells from Duchenne muscular dystrophy patients through genomic excision of exon 51 by zinc finger nucleases. Molecular Therapy. 2015;**23**(3):523-532. DOI: 10.1038/mt.2014.234. Epub 2014 Dec 10

[176] Popplewell L, Koo T, Leclerc X, Duclert A, Mamchaoui K, Gouble A, et al. Gene correction of a duchenne muscular dystrophy mutation by meganuclease-enhanced exon knock-in. Human Gene Therapy. 2013;**24**(7): 692-701. DOI: 10.1089/hum.2013.081

[177] Cordova G, Negroni E, Cabello-Verrugio C, Mouly V, Trollet C. Combined therapies for duchenne muscular dystrophy to optimize treatment efficacy. Frontiers in Genetics. 2018;**9**:114. DOI: 10.3389/fgene.2018. 00114

[178] Nance ME, Duan D. Perspective on adeno-associated virus capsid modification for duchenne muscular dystrophy gene therapy. Human Gene Therapy. 2015;**26**(12):786-800. DOI: 10.1089/hum.2015.107. Epub 2015 Oct 15

[179] Nelson CE, Hakim CH, Ousterout DG, Thakore PI, Moreb EA, Castellanos Rivera RM, et al. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science. 2016;**351**(6271):403-407. DOI: 10.1126/ science.aad5143. Epub 2015 Dec 31

[180] Wang JZ, Wu P, Shi ZM, Xu YL, Liu ZJ. The AAV-mediated and RNAguided CRISPR/Cas9 system for gene therapy of DMD and BMD. Brain & Development. 2017;**39**(7):547-556. DOI: 10.1016/j.braindev.2017.03.024. Epub 2017 Apr 5

[181] Zhu P, Wu F, Mosenson J, Zhang H, He TC, Wu WS. CRISPR/Cas9-mediated genome editing corrects dystrophin mutation in skeletal muscle stem cells in a mouse model of muscle dystrophy. Molecular Therapy—Nucleic Acids. 2017;**7**:31-41. DOI: 10.1016/j. omtn.2017.02.007. Epub 2017 Feb 28
